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ABSTRACT
Background We aimed to describe the main features
of Behçet’s disease (BD) in children in the largest
prospective cohort to date and to propose a
classiﬁcation.
Methods An international expert consensus group was
formed to deﬁne a data set of minimal symptoms for the
inclusion of patients. Patients were entered prospectively
during 66 months. Experts classiﬁed patients on a
consensus basis. The concordance of two international
classiﬁcations was analysed in conﬁrmed patients with
BD. Comparisons of subgroups of patients helped deﬁne
consensus criteria. BD-associated clinical manifestations
were also investigated in three control diseases extracted
from an independent data set (Eurofever).
Findings In total, 42 centres from 12 countries
included 230 patients; data for 219 (M/F ratio=1) could
be analysed. The experts classiﬁed 156 patients (71.2%)
as having conﬁrmed BD. Males more often than females
showed cutaneous, ocular and vascular symptoms and
females more often genital aphthosis. Age at disease
onset and skin and vascular involvement were lower for
European than non-European children. Oral aphthosis
was the presenting sign for 81% (179/219) of patients.
The mean delay to the second symptom was 2.9
±2.2 years. International classiﬁcations were not
concordant with the expert classiﬁcation. Our paediatric
classiﬁcation contains six categories, a minimum of three
signs (each in a distinct category) deﬁning paediatric BD.
Three clinical signs discriminated our cohort from the
Eurofever cohorts.
Interpretation We present a comprehensive
description of a large cohort of patients from both
European and non-European countries and propose the
ﬁrst classiﬁcation of paediatric BD for future therapeutic
trials.
INTRODUCTION
Behçet’s disease (BD) is a systemic inﬂammatory
condition sharing the clinical features of both auto-
inﬂammatory disease and vasculitis.1 2 Its patho-
genesis is still unclear, but the combination of
genetic factors affecting the immune regulation and
undetermined environmental triggers may explain
the variability disease expression.3 The clinical
spectrum of BD comprises a number of organ
involvements; the pattern of skin lesions and the
peculiar occurrence of thrombosis in all types of
vessels represent important clues. In fact, the
disease is now classiﬁed as a ‘variable vessel vascu-
litis’, which highlights the involvement of any
artery and vein.4 Oral aphthosis is present in
almost all patients with BD (98%).5 As well, BD
manifestations are recurrent. Some heal without
scar or sequelae, but others cause substantial mor-
bidity, such as ophthalmological manifestations,
which may cause blindness and vascular and
cardiac involvements, the main causes of mortality.6
Although generally recognised in adulthood, the
ﬁrst BD symptoms may start early in life, and the
disease is rarely completed before the age of
16 years in 4–26% of cases.7 At this age, the fre-
quency of uveitis is lower than in adults and the
rate of familial aggregation is high, which strongly
suggests a genetic component.8–11
BD is diagnosed when a patient presents a com-
bination of symptoms among the most frequently
observed and/or the most typical of the disease.
Several international groups have attempted to
propose clinical criteria for classiﬁcation or diag-
nostic criteria in adult patients with BD. The most
currently used are those developed by an inter-
national study in 1990 (see online supplementary
table S1).12 The sensitivity of the criteria appeared
relatively low because they were not established in
accordance with the geographical variations of BD
phenotype. Revised criteria were proposed from a
multinational collaboration of 27 countries: in add-
ition to mucocutaneous and ocular features, the cri-
teria included neurological and vascular
involvement.13 However, we lack a suitable, vali-
dated deﬁnition of BD in children, and the diagno-
sis remains challenging. The diagnostic criteria of
paediatric BD must be sensitive as well as speciﬁc
because several other conditions, especially autoin-
ﬂammatory diseases, inﬂammatory bowel diseases
and immunodeﬁciency, can mimic BD.
The Paediatric Behçet’s Disease (PEDBD) study
was established to identify the clinical course of
children presenting few symptoms of BD and for
whom other diagnoses were ruled out. We wanted
also to provide a paediatric BD classiﬁcation to
help in performing future therapeutic trials.
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AIMS OF THE PEDBD STUDY
The primary objective was to establish a prospective cohort of
paediatric patients presenting a minimal set of BD signs. The
secondary objectives were as follows:
▸ to identify a subgroup of patients with conﬁrmed paediatric
BD by an adjudication process involving expert consensus;
▸ to deﬁne the natural history of BD by type of symptoms and
their chronology of appearance;
▸ to test the concordance of two international BD classiﬁcation
criteria with the developed expert classiﬁcation, then deﬁne a
paediatric classiﬁcation;
▸ to perform an external validation of the new paediatric clas-
siﬁcation by using data from patients with other autoinﬂam-
matory diseases as negative controls.
PATIENTS AND METHODS
Study design
First step: establishing an expert consensus group and minimal
set of symptoms
The expert committee of four adult specialists and three paedia-
tricians deﬁned the minimal set of symptoms as follows: recur-
rent oral aphthosis, at least three times a year, associated with at
least one of the following: genital ulceration or aphthosis, vessel
thrombosis or aneurysm, erythema nodosum, acneiform lesions,
papulopustular lesions, skin ulceration or aphthosis, positive
pathergy test, uveitis (post or panuveitis), retinal vasculitis and
family history of BD (if documented).
Inclusion/exclusion criteria for the PEDBD cohort
Patients needed to fulﬁl the criteria established by the expert
committee and to sign an informed consent for participation
according to the regulations of participating countries. They had
to present a ﬁrst symptom before age 16 and have no concomi-
tant diseases interfering with BD evaluation. These were new or
already known patients (maximum 3 years) and could be fol-
lowed prospectively for at least 4 years. Exclusion criteria were
patients who did not meet at least one of these criteria.
Second step: establishing an electronic database, international
collaboration and data entry
An online database was designed following the national regula-
tions in France and in accordance with local regulations in each
participating countries. Inclusion and update visits were
recorded into a standardised format. Our clinical research unit
(HA, AA, CP) provided data management. The Paediatric
Rheumatology European Society, Paediatric Rheumatology
INternational Trials Organisation and International BD society
members entered their patients anonymously.
Third step: annual review and case adjudication
The expert committee performed an annual chart review. In a
round-robin format, the members collected votes to classify
patients as having conﬁrmed, probable and uncertain or no BD.
Consensus was obtained with 80% agreement. Charts for
patients were reviewed more than once, if necessary, until the
PEDBD group closed the study, during the last meeting on 6
February 2014. Patients without diagnostic consensus at this
deadline were not classiﬁed.
Fourth step: statistical analysis
The comparison of conﬁrmed and unconﬁrmed patients with BD
provided a preliminary classiﬁcation, which was secondarily
endorsed by consensus. Patients from the Eurofever registry were
negative controls (see online supplementary information 1).4
Variables included in the PEDBD score were anonymously
extracted and analysed. Criteria deﬁning BD were based on
symptoms appearing before the expert classiﬁcation, and the ana-
lysis of natural history was based on symptoms collected during
the whole study. For univariate analyses, continuous variables are
summarised with mean (SD) and categorical variables as number
(percentage). Missing data were described by calculating the per-
centage of the total effective data and were excluded from
further analyses. For bivariate analyses, the primary outcome was
the expert classiﬁcation (conﬁrmed and unconﬁrmed BD).
Symptoms, determinants of symptoms and potential associated
factors were compared. The association of qualitative variables
and the primary outcome (conﬁrmed BD) was analysed by
Pearson’s χ2 or Fisher’s exact test and that of quantitative vari-
ables and the primary outcome was by Student’s t or Mann–
Whitney U test. For multivariate analysis, a logistic regression
model with stepwise selection was used to investigate the associ-
ation of symptoms and conﬁrmed BD, reporting ORs and 95%
CIs. Signiﬁcance at p≤0.20 was required to be included and
remain in the model. Potential interactions between variables
were tested. A sensitivity analysis was performed to analyse
whether headache should be included in neurological symptoms.
For each subject, the number of criteria was calculated from
symptoms retained in the model plus oral aphthosis. The optimal
number of criteria distinguishing conﬁrmed and unconﬁrmed BD
was established by receiver operating characteristic (ROC) curve
analysis. To assess sensitivity and speciﬁcity, the agreement
between the BD classiﬁcation and alternative classiﬁcations was
analysed by the Kappa method.12 13 Symptom patterns and path-
ology type were explored by multiple correspondence analyses.
Statistical analyses involved use of SAS V.9.3 (SAS Institute, Cary,
North Carolina, USA).
RESULTS
The total duration of the PEDBD study from the ﬁrst to the last
inclusion was 66 months.
Fulﬁlment of inclusion and non-inclusion criteria, and minor
protocol deviations
In total, 227 patients were eligible and agreed to be included in
the study; 53 (23.3%) were ≥16 years old at the inclusion visit.
Overall, 220 had at least one symptom in addition to recurrent
oral aphthosis; 7/227 (3.1%) had oral aphthosis associated with
a family history of BD, and 8/227 (3.5%) who presented or
showed another disease during the PEDBD study were
excluded. Finally, data for 219 patients could be analysed during
717 follow-up visits (mean 3.2 visits per patient) (see online
supplementary ﬁgure S1).
Epidemiological data and whole cohort
The 219 patients (109 males) originated from 42 centres in 12
countries (not shown). The ethnic distribution was approxi-
mately one-third European Caucasian, one-third Middle Eastern
Caucasian and one-third North African (not shown). The mean
age at ﬁrst symptom was 7.4±4.2 years (median 7 years, range
0–15.9 years). In addition to recurrent oral aphthosis, patients
had genital aphthosis 104/219 (47.5%), necrotic folliculitis, pus-
tular or acneiform lesions 60/198 (30.3%), erythema nodosum
37/198 (18.7%), pathergy 42/94 (44.7%), anterior uveitis 52/
219 (23.7%), posterior uveitis 47/219 (21.5%), retinal vasculitis
20/219 (9.1%), papilledema 17/219 (7.8%), anterior uveitis in
association with at least another posterior ﬁnding 29/52
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(18.6%), venous thrombosis 21/219 (9.6%), and arterial throm-
bosis or aneurysm 4/219 (1.8%).
Classiﬁcation of PEDBD patients and comparison
of conﬁrmed and unconﬁrmed BD
The expert committee classiﬁed 156/219 patients (71.23%) as
having conﬁrmed BD and 63 as having unconﬁrmed BD (prob-
able 26, uncertain 14, no consensus 18, not BD 5). Patients
with conﬁrmed and unconﬁrmed BD were comparable in sex
ratio (M/F=1), family history of BD, consanguinity and disease
duration since the ﬁrst symptom to the ﬁrst and last visit
(table 1). However, age at ﬁrst symptom, at ﬁrst suspicion and
at BD conﬁrmation was higher for conﬁrmed than unconﬁrmed
patients. BD conﬁrmation was associated with clinical symptoms
of genital aphthosis (p=0.0004) and any of the following: cuta-
neous (pathergy test excluded from the analysis; p=0.0084),
neurological (p=0.0022), ocular (p=0.0002) and vascular
symptoms (p=0.0052) (see online supplementary table S2). It
was associated with the cutaneous symptoms necrotic follicul-
itis/acneiform lesions/folliculitis (p=0.0169) and erythema
nodosum (p=0.0279), as well as anterior and posterior uveitis
(p=0.0150 and 0.0029), retinal vasculitis (p=0.0010) and
papilledema (p=0.0022) but not presence of human leucocyte
antigen B51 (p=0.2965) (not shown).
Descriptive data for the 156 patients with conﬁrmed BD
Of the 156 patients with conﬁrmed BD, half were males (n=78)
(table 1); about half (56.41%, n=88) lived in Europe (not
shown). Among them, 86 (53.8%) were <16 years at BD con-
ﬁrmation. The main categories of clinical symptoms at BD con-
ﬁrmation are given in online supplementary table S2. More
detailed clinical information is available in the online supple-
mentary ﬁle additional information no 3.
Gender differences
The mean number of attacks per year of oral aphthosis was
similar for females and males with conﬁrmed BD (11.32±10.87
and 13.16±14.23), as was the mean number of attacks of genital
ulceration (3.42±4.46 and 3.85±4.40) (not shown). However,
the sexes differed in distribution of clinical symptoms (ﬁgure 1).
Indeed, genital ulceration was associated more with females than
males (p=0.0006), and ocular symptoms as a whole and vascular
symptoms were associated more with males (p=0.0039 and
0.0199). Considered individually, none of the cutaneous symp-
toms differed between the sexes. Among the ocular symptoms,
males more than females showed posterior uveitis (p=0.0004),
retinal vasculitis (p=0.0265) and papilledema (p=0.0348), as
well as involvement of both eyes (p=0.0193), visual acuity <1/
10 (p=0.5766) and venous thrombosis (p=0.0265). Cranial
Table 1 Epidemiological characteristics of the 219 Paediatric
Behçet’s Disease (PEDBD) patients with confirmed and unconfirmed
Behçet’s disease (BD)
Characteristics
Confirmed BD
n=156
Unconfirmed BD
n=63 p Value
Gender, males/females, no. (%) 78 (50)/79 (50) 31 (49.2)/32 (50.8) 0.9153
Consanguinity, no. (%)* 6 (3.9) 4 (6.4) 0.4802
Familial case, no. (%) 32 (24.4) 16 (29.1) 0.5071
Age at first symptom, years 7.83±4.39 6.19±3.64 0.0105
Age at first suspicion by the
physician
11.33±3.84 10.04±3.59 0.0123
Age at diagnosis, years† 13.87±3.82 – –
Age at last visit, years 14.89±4.01 13.14±3.78 0.0020
Time from first symptom to
first visit
4.54±3.35 4.85±3.88 0.8367
Disease duration, years‡ 7.11±3.58 6.94±4.28 0.6485
Data are mean±SD unless indicated.
*Unknown for five patients.
†BD diagnosis/confirmation: age at which the patient could be classified as having
definite BD by the consensus of experts.
‡Disease duration: mean time between the first symptoms of BD to the last follow-up
visit in the PEDBD cohort.
Figure 1 Frequency of symptoms in 156 patients with conﬁrmed Behçet’s disease according to the gender.
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nerve palsy was more common, although not signiﬁcantly, in
females than males (p=0.1165).
Regional differences
The age at ﬁrst BD symptom was signiﬁcantly lower for patients
in European than non-European countries (6.84±4.66 vs 9.12
±3.67; p=0.0017). European patients frequently showed articu-
lar (p=0.0527) (especially axial joints; p=0.0061 vs peripheral;
p=0.0892), gastrointestinal (p<0.0001) and neurological symp-
toms (including headaches: p<0.0001; without headaches but
with papilledema: p=0.05), and fever (p<0.0001). Conversely,
some symptoms more frequent for non-European patients
included necrotic folliculitis, pseudo folliculitis and acneiform
lesions (each p<0.05). European and non-European patients did
not differ in individual ocular symptoms, but European patients
more frequently showed bilateral symptoms (p=0.0405) that
resulted in visual loss (visual acuity <1/10; p=0.0447). Among
neurological symptoms without headaches, only long-tract dys-
function was more frequent, although not signiﬁcant, in
European than non-European patients (p=0.0687). Vascular
symptoms were more frequent in non-European patients.
Chronology of symptoms and pathways of entry in BD
through the PEDBD cohort study
Oral aphthosis was the presenting symptom for 81% (179/219)
of patients, followed by genital ulceration, skin symptoms and
fever (20.5%). The chronology of symptoms in patients with
and without conﬁrmed BD is shown in ﬁgure 2 and online sup-
plementary ﬁgure 2. The ages of onset of symptoms by classiﬁ-
cation are given in table 2. The mean ages at onset of oral
aphthosis (8.74±4.21) and neurological symptoms were signiﬁ-
cantly higher for patients with conﬁrmed than unconﬁrmed BD
(p=0.0143 and 0.0144, respectively). The median delay
between the ﬁrst and second wave of symptoms in all patients
was 2 years (range 1–12 years; mean 2.9±2.2 years) (see online
supplementary ﬁgure 3), and the median delay between the
second and third and third and fourth waves was 1.5 years
(range 1–8 years, mean 2±1.6). New symptoms occurring
during follow-up were more frequent for patients with than
without conﬁrmed BD (not shown). The mean delay between
the ﬁrst symptom and age at BD conﬁrmation was 6.0±3.5
years. One patient died of multiple thromboses.
Figure 2 Chronology of symptoms in 156 patients with conﬁrmed Behçet’s disease.
Table 2 Age of onset of Behçet’s disease (BD) symptoms for
patients with confirmed and unconfirmed BD by expert classification
(Paediatric Behçet’s Disease (PEDBD))
PEDBD
classification
Confirmed BD
n=156
Unconfirmed BD
n=63
p ValueAge
No. of
patients Age
No. of
patients
Oral aphthosis 8.74±4.21 156 7.32±3.77 63 0.0143
Genital ulceration 11.23±4.32 86 10.67±3.56 18 0.3083
Cutaneous signs 10.36±4.30 104 8.85±4.51 26 0.1072
Ocular signs 10.94±3.62 71 9.18±3.22 11 0.1192
Articular signs 10.02±3.79 64 9.67±3.66 24 0.6990
Gastrointestinal
signs*
8.87±4.60 46 8.17±3.75 18 0.4539
Neurological
signs*
10.95±3.95 93 8.25±2.80 51 0.0144
Vascular signs 11.26±3.89 23 9 1 0.6104
Fever 8.63±4.64 68 8.30±4.56 23 0.7555
Cardiac signs 10.29±3.55 7 15 1 0.2600
Pulmonary signs 11.33±5.02 9 15 1 0.4561
Data are mean±SD.
*Neurological signs include patients with headaches and gastrointestinal signs include
those with abdominal pain. Detailed clinical information is available in the online
supplementary information file.
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Comparison of expert classiﬁcation with international
criteria for BD
In all, 115/156 PEDBD patients fulﬁlled the ISG criteria (sensi-
tivity 73.7%, speciﬁcity 100%; κ coefﬁcient 0.62). In general,
PEDBD patients discordant with the ISG criteria had only one
of genital, skin and ocular symptoms. The new international
PEDBD classiﬁcation evaluated without the pathergy test had
higher sensitivity (91.7%; 143/156 patients fulﬁlling both classi-
ﬁcations) but lower speciﬁcity (42.9%, κ=0.39). The addition
of the pathergy test did not improve performance (κ=0.44; sen-
sitivity 96.2%, speciﬁcity 41.3%). The discordance was not
improved with oral plus genital aphthosis or oral aphthosis plus
ocular symptoms (κ=0.49).
Preliminary classiﬁcation of paediatric BD according to the
PEDBD data
Symptoms associated with BD conﬁrmation were considered
simultaneously. The categories of signs were genital ulceration
and cutaneous, ocular, neurological and vascular symptoms.
Several hypotheses were tested for neurological symptoms
because only headaches and papilledema appeared signiﬁcantly
associated with conﬁrmed BD. Two of the hypotheses are given
in online supplementary table 3. All experts agreed to retain
neurological symptoms as a whole; indeed, neurological symp-
toms were found in only conﬁrmed patients with BD. The mean
number of symptoms at the time of the expert classiﬁcation was
signiﬁcantly higher for patients with conﬁrmed than
unconﬁrmed BD (3.15±0.89 vs 2.08±0.6; p<0.0001) (not
shown). The ROC curve for three symptoms gave sensitivity
77% and speciﬁcity 88% (not shown). Taking into account both
the category of signs and number of signs signiﬁcantly associated
with the experts’ conﬁrmation of BD and the experts’ consen-
sus, we proposed a ﬁrst classiﬁcation of BD in children (table 3).
Comparisons with the Eurofever cohort
The Eurofever registry provided data for 410 patients (220
males; mean age 7.6±3.8 years, range 6 months to 16 years)
with diseases distinct from BD, who were negative controls (ie,
periodic fever adenitis pharyngitis and aphthosis (PFAPA) syn-
dromes, n=259; cryopyrin-associated periodic syndrome
(CAPS), n=86; and mevalonate kinase deﬁciency (MKD),
n=65). The mean age for our BD-conﬁrmed patients was
higher (p<0.0001). Signiﬁcant differences appeared for all cat-
egories and testing different hypotheses for ocular and neuro-
logical symptoms (table 4). For the Eurofever patients, the mean
number of BD symptoms was lower for conﬁrmed than
unconﬁrmed patients with BD in the PEDBD population
(p<0.0001) (eg, PFAPA 0.63±0.52, CAPS 0.52±0.76 and
MKD 0.8±0.71 vs 3.15±0.89 and 2.08±0.6, respectively).
Multiple correspondence analyses between PEDBD and
Eurofever are given in online supplementary ﬁgure S4.
DISCUSSION
BD in children is rare and challenging to recognise. We aimed
to describe the main features of the disease in the largest pro-
spective cohort to date and propose a classiﬁcation of paediatric
BD. Among the 219 children included (equal males and
females, symptoms appearing before age 16), the experts con-
ﬁrmed BD in 156 (71.2%). Males more often than females had
cutaneous, ocular and vascular symptoms and females more
often than males had genital aphthosis. Oral aphthosis was the
presenting sign in 81% of patients. International classiﬁcations
were not concordant with the experts’ classiﬁcation. Our paedi-
atric classiﬁcation contains six categories, a minimum of three
deﬁning paediatric BD (table 3).
The main strengths of the PEDBD study are the international
collaboration and its prospective study design assessing the
natural history of BD. In addition, it is the ﬁrst attempt to
emphasise the shortcomings or limitations of the adult criteria
for the paediatric population and introducing the main features
in paediatric BD in the largest cohort of patients. Oral aphthosis
Table 3 Consensus classification of paediatric Behçet’s disease (BD)
Item Description Value/item
Recurrent oral aphthosis At least three attacks/year 1
Genital ulceration or
aphthosis
Typically with scar 1
Skin involvement Necrotic folliculitis, acneiform lesions,
erythema nodosum
1
Ocular involvement Anterior uveitis, posterior uveitis, retinal
vasculitis
1
Neurological signs With the exception of isolated
headaches
1
Vascular signs Venous thrombosis, arterial thrombosis,
arterial aneurysm
1
Three of six items are required to classify a patient as having paediatric BD.
Table 4 Frequency of symptoms among diseases and confirmed and unconfirmed paediatric Behçet’s disease (BD)
Disease
PFAPA
n=259
MKD
n=65
CAPS
n=86
Unconfirmed BD
n=63
Confirmed BD
n=156 p Value*
Age, mean±SD 6.95±3.42 8.73±4.11 8.88±4.24 11.91±3.82 13.25±3.88 <0.0001
Oral aphthosis 153 38 12 63 156 <0.0001
Genital aphthosis 0 1 0 20 91 <0.0001
Ocular sign† 1 2 6 12 67 <0.0001
Ocular signs‡ 1 2 23 12 73 <0.0001
Neurologic signs 42 25 35 15 72 <0.0001
Neurologic signs¶ 6 8 26 0 37 <0.0001
Vascular symptoms 0 1 0 2 27 <0.0001
Data are no. (%) unless indicated.
*By χ2 test.
†Ocular sign: includes at least one of anterior and posterior uveitis and retinal vasculitis.
‡Ocular signs: includes at least one of anterior and posterior uveitis, retinal vasculitis and papilledema.
¶Neurological signs: calculated without headaches and with papilledema.
CAPS, cryopyrin-associated periodic syndrome; MKD, mevalonate kinase deficiency; PFAPA, periodic fever adenitis pharyngitis and aphthosis.
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was mandatory for inclusion because of its high frequency in
children with BD (95%).9 11 14–17 Symptoms such as vascular
symptoms and family history were included because they repre-
sented a considerable share of the features of paediatric patients.
To attain our ﬁrst objective, to establish a prospective cohort of
paediatric patients presenting a minimal set of BD signs, a
remarkable effort was made during 7 years to update patient
information and classify the disease each year, independent of
any predeﬁned criteria. Conﬁrmed BD was associated with
genital aphthosis, skin manifestations, neurological and vascular
symptoms as well as number of attacks of oral aphthosis, visual
acuity <1/10 and the presence of a median number of three
symptoms. Patients with conﬁrmed BD had an equal sex ratio
and most lived outside Europe (56%). Cutaneous signs were the
most frequent, and ocular symptoms and genital aphthosis were
less frequently observed than in adults. Females more often than
males had genital aphthosis, whereas males more often than
females had ocular and vascular symptoms.7 9 18 19 Age at onset
and articular, gastrointestinal and neurological symptoms during
follow-up were more frequent in European than non-European
patients, who also had had more skin and vascular involvement,
in accordance with several BD cohorts and registries.7 9 20 21
Interestingly, European patients more frequently had bilateral
lesions (p=0.0405) and visual loss (p=0.0447). A lower degree
of awareness of BD uveitis in European than non-European
patients could delay appropriate treatment. The second BD
symptom appeared at a median of 2 years (mean 2.9±2.2) and
BD conﬁrmation at 6.0±3.5 years.8 Oral ulceration was the ﬁrst
symptom in most cases and was generally followed by cutaneous
signs, fever, articular or gastrointestinal signs. Ocular and vascu-
lar symptoms appeared later in general. The ocular involvement
was associated with severe prognosis for 12.3% (27/219) of
patients with visual acuity <1/10; three had permanent
blindness.
To meet our ﬁnal objective, we compared our 156 conﬁrmed
patients with BD with two of the international classiﬁcations
designed for an adult population.12 13 Both had low concord-
ance with our expert classiﬁcation. We propose a new consensus
classiﬁcation for paediatric BD (table 3). Six categories of symp-
toms were considered with their descriptions. Papilledema and
headaches were the only neurological symptoms signiﬁcantly
associated with conﬁrmed BD. Finally, we agreed to consider
neurological symptoms as a whole but without headaches,
which are not speciﬁc enough in BD.22 Our PEDBD classiﬁca-
tion does not consider a positive pathergy test result and does
not mention oral aphthosis as a mandatory criteria. All symp-
toms categories have the same weight, especially because we do
not know their respective frequencies in the general paediatric
population. The new paediatric BD classiﬁcation could differen-
tiate conﬁrmed BD, with a signiﬁcantly increased number of
symptoms, from unconﬁrmed BD and PFAPA, MKD and CAPS,
as negative controls.
To conclude, we have reported the widest cohort study ever
performed to deﬁne paediatric BD and its natural history. The
contribution of three cohorts of children from the Eurofever
registry reinforces the validity of the new classiﬁcation of paedi-
atric BD, which will be a reference for further therapeutic trials,
even if it still requires external validation by an independent
cohort of patients with paediatric BD.
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